27 Apr ADA Statement Regarding Lilly’s Announcement of Weight Loss in Adults with Obesity and Type 2 Diabetes with Tirzepatide (Mounjaro™) Injections
Statement from Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA, regarding the Lilly statement this of April 27, 2023.
The final results of this SURMOUNT-2 study will be announced at the ADA SciSessions in June, 2023.
“Tirzepatide was effective at having people with diabetes lose 15.7 % of their body weight which is substantial and highly clinically meaningful. The weight loss was less than what has been reported with tirzepatide in those without diabetes as has been seen with other weight loss medication trials.
“The ADA Standards of Care recommends personalized weight loss goals for those with diabetes and obesity with maximum benefit seen with weight reductions as high as 15% (as seen here) are achieved. This further supports the role of tirzepatide in the treatment of individuals with type 2 and obesity. We are excited to see the full results of the SURMOUNT-2 study, which will be presented at the American Diabetes Association’s 83rd Scientific Sessions in June.”
Last Updated on April 27, 2023 by Marie Benz